(BCAB) Bioatla - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09077B1044

Antibody-Drug Conjugates, T-Cell Therapies, Cancer

BCAB EPS (Earnings per Share)

EPS (Earnings per Share) of BCAB over the last years for every Quarter: "2020-03": -0.07, "2020-06": -0.29, "2020-09": -0.38, "2020-12": -0.49, "2021-03": -0.56, "2021-06": -0.9, "2021-09": -0.68, "2021-12": -0.69, "2022-03": -0.65, "2022-06": -0.77, "2022-09": -0.68, "2022-12": -0.63, "2023-03": -0.55, "2023-06": -0.75, "2023-09": -0.7, "2023-12": -0.56, "2024-03": -0.48, "2024-06": -0.44, "2024-09": -0.22, "2024-12": -0.3, "2025-03": -0.26,

BCAB Revenue

Revenue of BCAB over the last years for every Quarter: 2020-03: 0.089, 2020-06: 0.19, 2020-09: 0.15, 2020-12: 0, 2021-03: 0, 2021-06: 0.25, 2021-09: 0.15, 2021-12: 0.25, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 1.706, 2024-03: 0, 2024-06: 0, 2024-09: 11, 2024-12: 0, 2025-03: 0,

Description: BCAB Bioatla

BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted antibody-based therapeutics for the treatment of various solid tumor cancers. The companys innovative approach focuses on conditionally active biologics (CABs) that are designed to remain inactive until they reach the tumor site, thereby minimizing side effects and enhancing therapeutic efficacy.

The companys pipeline includes several promising candidates, such as mecbotamab vedotin (BA3011), an antibody-drug conjugate (ADC) targeting undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC), and ozuriftabmab vedotin (BA3021), another ADC aimed at treating melanoma and squamous cell carcinoma of the head and neck. Other notable candidates in development include Evalstotug (BA3071), a CAB anti-CTLA-4 antibody for various cancers, BA3182, a bispecific candidate for adenocarcinomas, and BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on multiple solid tumors.

From a technical analysis perspective, the stocks current price is $0.38, below its 20-day simple moving average (SMA) of $0.45, indicating a potential downtrend. However, the 50-day SMA is at $0.38, suggesting a possible stabilization. The average true range (ATR) of $0.05 indicates a relatively high volatility of 12.84%. Given the current technical indicators, a potential support level is seen around the 52-week low of $0.27, while resistance is near the 52-week high of $2.37.

Fundamentally, BioAtlas market capitalization stands at $25.04M USD, with no P/E ratio due to the companys current lack of profitability, reflected in its negative return on equity (RoE) of -357.92%. The absence of earnings makes traditional valuation challenging, but the companys progress in its clinical-stage pipeline could be a significant driver for future growth.

Forecasting BioAtlas stock performance involves analyzing both technical and fundamental data. Given the current downtrend and high volatility, a cautious approach is warranted. If the company successfully advances its pipeline candidates through clinical trials, particularly mecbotamab vedotin and ozuriftabmab vedotin, this could positively impact the stock. A potential price target could be near the 52-week high of $2.37 if the company achieves significant milestones, such as positive trial results or FDA approvals. However, failure to advance its pipeline could lead to further decline towards the 52-week low of $0.27. Therefore, investors should closely monitor the companys clinical updates and adjust their strategies accordingly.

Additional Sources for BCAB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

BCAB Stock Overview

Market Cap in USD 24m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2020-12-16

BCAB Stock Ratings

Growth Rating -86.9
Fundamental -
Dividend Rating 0.0
Rel. Strength -66.4
Analysts 4.25 of 5
Fair Price Momentum 0.15 USD
Fair Price DCF -

BCAB Dividends

Currently no dividends paid

BCAB Growth Ratios

Growth Correlation 3m 16.5%
Growth Correlation 12m -79.6%
Growth Correlation 5y -93.5%
CAGR 5y -61.79%
CAGR/Max DD 5y -0.62
Sharpe Ratio 12m -1.29
Alpha -96.72
Beta 2.590
Volatility 101.53%
Current Volume 492.3k
Average Volume 20d 505k
Stop Loss 0.4 (2.6%)
What is the price of BCAB shares?
As of July 09, 2025, the stock is trading at USD 0.39 with a total of 492,263 shares traded.
Over the past week, the price has changed by -0.74%, over one month by -23.56%, over three months by +45.52% and over the past year by -69.44%.
Is Bioatla a good stock to buy?
No, based on ValueRay´s Analyses, Bioatla (NASDAQ:BCAB) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -86.88 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCAB is around 0.15 USD . This means that BCAB is currently overvalued and has a potential downside of -61.54%.
Is BCAB a buy, sell or hold?
Bioatla has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy BCAB.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for BCAB share price target?
According to our own proprietary Forecast Model, BCAB Bioatla will be worth about 0.2 in July 2026. The stock is currently trading at 0.39. This means that the stock has a potential downside of -53.85%.
Issuer Target Up/Down from current
Wallstreet Target Price 8.3 2035.9%
Analysts Target Price 8.3 2035.9%
ValueRay Target Price 0.2 -53.8%